Grand Pharmaceutical Group Limited (stock code: 00512.HK), abbreviated as “Grand Pharma”, is an international pharmaceutical company of technological innovation, integrating pharmaceutical technology, nuclear medicine anti-tumor diagnosis and treatment, cerebro-cardiovascular precision intervention diagnosis and treatment technology and biotechnology.
Currently, the Group has more than 10,000 employees globally, more than 30 subsidiaries at home and abroad, 5 technology platforms and 9 research and development centers, more than 200 products on the National Reimbursement Drug List, and 16 products which worth over 100 million dollars each. The Company has been committed to three major business fields, with its business coverage across various segments including cerebro-cardiovascular, Eye, Nose & Throat (ENT), respiratory and critical and severe diseases, pharmaceutical raw materials, nuclear medicine anti-tumor diagnosis and treatment, cerebro-cardiovascular precision intervention diagnosis and treatment and amino acids.
Grand Pharma has always adhered to the spirit of “dare to be the first and share the success”, with the business philosophy of “provide high-quality products with sincerity and integrity”.
